



Dear Shareholder

We have today released our Annual Report for the year ended 31 March 2020. We invite you to read this on our website at www.pacifiedgedx.com/investors/shareholder-reports/.

We continue to make good progress in our journey to commercialise our Cxbladder tests in the global market. In FY20, all our key performance metrics increased year on year.

Highlights for the period included the publication of three additional peer reviewed papers in support of Cxbladder; inclusion in the National Comprehensive Cancer Network (NCCN) guidelines in the US; increased adoption and commercial use by New Zealand's public healthcare providers and growing recognition and adoption by urologists in the US and New Zealand.

The past few months have been an extraordinary time for countries and businesses around the globe, as together we have faced the challenges of Covid-19. We have seen an acceleration of trends that have been progressing slowly for many years, such as the move to telehealth and new ways of doing things are quickly becoming the norm.

For Pacific Edge, the global pandemic circumstances have highlighted the benefits of our Cxbladder tests, providing assurance to patients, simplifying the diagnostic process and allowing for easy, non-invasive in-home sample collection, all while providing high quality results for clinicians.

The benefits of this additional utility was reflected in the recent agreement with leading US healthcare provider, Kaiser Permanente, which has approved the commercial use of Cxbladder by their urologists for patients being evaluated for bladder cancer. This is a significant milestone achievement for our company.

In all our markets, our commercial focus remains on the large scale, blue chip healthcare organisations, such as Kaiser Permanente, which can benefit from adopting Cxbladder and which will also deliver greater scale and volumes over the long term.


We remain committed to realising the significant opportunity that exists for Cxbladder, and we are progressing in a number of areas which will help us achieve our goals of growing our global reach, building and strengthening our customer base and increasing sales and adoption, all of which will drive greater cash revenue.

Given the current environment, our Annual Meeting will be a virtual meeting on 5 August 2020 and we welcome you to sign in and participate online. Further details on the Meeting will be sent to shareholders in the near future.

Thank you for your continued support.



Chris Gallaher
Chairman



David Darling
Chief Executive Officer

26 June 2020

PROGRESS IN FY20

COMMERCIAL GROWTH: Increasing number of customers and urologists adopting and using Cxbladder; 14% increase in Operating Revenue and 7% increase in Total Laboratory Throughput.

PUBLICATION OF FURTHER PEER-REVIEWED PAPERS highlighting Cxbladder's outperformance and adding significant additional clinical utility evidence in support of Cxbladder.

INCLUSION IN USA'S NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) GUIDELINES as an approved clinical intervention for patients being monitored for recurrence of urothelial cancer (UC).

USA: Growing recognition and adoption by the targeted large healthcare institutions in the USA.

LCD PROGRESS: Updated dossier of clinical evidence accepted for formal review by the Centers for Medicare and Medicaid Services (CMS) in the USA, as part of the process for inclusion in the Local Coverage Determination (LCD).

NEW ZEALAND: Continuing adoption and increasing commercial use of Cxbladder by New Zealand public healthcare providers (DHBs), consolidating New Zealand's world leading position.

SOUTH EAST ASIA: Continued progress in Southeast Asia with the five largest hospitals concluding their User Programmes. Analysis to be completed in FY21.

FUNDING: Successfully raised \$20.1m from existing and new investors through a fully underwritten placement and rights issue.


POST-PERIOD END

Leading non-profit US healthcare provider, Kaiser Permanente, approved the commercial use of Cxbladder by their urologists for patients being evaluated for bladder cancer.


We made good commercial progress in FY20 and all our key performance metrics increased year on year, with increased revenue and Laboratory Throughput and a growing number of urologists using our Cxbladder tests.

KEY METRICS

FY20 TOTAL LABORATORY TEST THROUGHPUT (COMMERCIAL TESTS AND USER PROGRAMMES)
+7% vs FY19 / 16,861 tests



FY20 LABORATORY THROUGHPUT BY REGION



FY20 FINANCIAL SNAPSHOT

Total Revenue \$5.2m

Revenue from test sales \$4.4m, up 14% year on year

Operating Expenses \$24.1m, up 5% on prior year

Net Operating Cashflow Improved 12% on prior year to \$(15.4)m

Net Loss After Tax \$(18.9)m

Cash, cash equivalents and short term deposits of \$14.8m as at 31 March 2020